Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea

Sanofi

Status: Completed

Conditions: Yellow Fever

Treatments: Biological: Stamaril®

Study type: Observational

Funder types: Industry

Identifiers

NCT03541694

STA10

Details and patient eligibility

About

This is a passive enhance safety surveillance (ESS) of Stamaril® vaccine in Korea. The objective is to collect suspected related adverse events following vaccination with Stamaril® in routine practice.

Full description

This ESS replaces the routing post-marketing surveillance required after product approval in Korea.

Enrollment: 622 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Vaccination with Stamaril® vaccine in routine practice in Korea